



---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**

**Current Report**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported):  
**November 11, 2003**

**BIOSANTE PHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**1-31812**  
(Commission File Number)

**58-2301143**  
(I.R.S. Employer Identification  
Number)

**111 Barclay Boulevard**  
**Lincolnshire, Illinois**  
(Address of Principal Executive Offices)

**60069**  
(Zip Code)

**(847) 478-0500**  
(Registrant's Telephone Number, Including Area Code)

**N/A**  
(Former Name or Former Address, If Changed Since Last Report)

---

---

**Item 5. Other Events and Regulation FD Disclosure.**

The information set forth below pursuant to Item 12 is hereby incorporated by reference into this Item 5.

**Item 12. Results of Operations and Financial Condition.**

On November 11, 2003, BioSante issued a press release announcing BioSante's financial results for the three-month and nine-month periods ended September 30, 2003. The text of the press release is as follows:

[BIOSANTE PHARMACEUTICALS, INC. LOGO]

**BioSante Pharmaceuticals, Inc.**  
111 Barclay Boulevard  
Lincolnshire, Illinois 60069  
[www.biosantepharma.com](http://www.biosantepharma.com)

FOR IMMEDIATE RELEASE

Amex: BPA

**BioSante Pharmaceuticals, Inc. Reports on  
Recent Events and Third Quarter Financial Results**

**Lincolnshire, Illinois (November 11, 2003)** - BioSante Pharmaceuticals, Inc. (Amex: BPA) today reported on recent corporate events and financial results for the three-month and nine-month periods ended September 30, 2003.

***Recent Corporate Events***

Recent highlights and important achievements include:

- Moved to the American Stock Exchange, effective October 1, 2003
- Closed on a \$10.3 million private placement in August 2003
- Reported positive results of long acting injectable insulin
- Received an NIH/SBIR grant for oral insulin development
- Initiated the one FDA-required pivotal Phase III trial of Bio-E-Gel™ (bio-identical estradiol gel) in menopausal symptoms after reporting positive Phase II/III results
- Reported positive interim results of the Phase II trial of LibiGel™ (bio-identical testosterone gel) in female sexual dysfunction

***Financial Results***

The company reported a net loss of approximately \$1.4 million or (\$0.12) per share for the quarter ended September 30, 2003, compared to a net loss of \$0.8 million or (\$0.11) for the same period in 2002. For the nine month period ended September 30, the company reported a net loss of \$4.3 million or (\$0.43) per share compared to a net loss of \$3.4 million or (\$0.49) per share for the same period the prior year.

---

The company's cash balance as of September 30, 2003 was approximately \$10.4 million, compared to \$4.9 million on December 31, 2002.

**About BioSante Pharmaceuticals, Inc.**

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems. Additional information is available online at [www.biosantepharma.com](http://www.biosantepharma.com).

**Contact:**

Phillip Donenberg CFO — 847-478-0500 ext 101;

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSANTE PHARMACEUTICALS, INC.**

By: /s/ Phillip B. Donenberg

---

Phillip B. Donenberg  
*Chief Financial Officer, Treasurer and Secretary*

Dated: November 11, 2003